Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Menarini-smyraf-Asia

More Like This

PR Newswire associated0

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

PR Newswire associated0

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

PR Newswire associated0

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

PR Newswire associated0

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories